<?xml version="1.0" encoding="UTF-8"?>
<p>Regarding neurotoxicity, grade 2 to 4 neuropathy was observed in 21.5% of patients (16 of 74 patients) (
 <xref rid="t3-1040138" ref-type="table">Table 3</xref>). Neuropathy was generally reported after cycle 3 of treatment. Bortezomib was stopped indefinitely in ten of the 11 patients with grade 3-4 neurotoxicity but not in cases of grade 2 toxicity. Partial reversibility of neuropathy was reported in 13 of the 16 patients (81%) with grade 2 to 4 neurotoxicity.
</p>
